|
EP0386960A3
(en)
|
1989-03-07 |
1991-10-23 |
American Cyanamid Company |
Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
|
|
US5861174A
(en)
|
1996-07-12 |
1999-01-19 |
University Technology Corporation |
Temperature sensitive gel for sustained delivery of protein drugs
|
|
US6286513B1
(en)
|
1998-10-22 |
2001-09-11 |
Jessie L. Au |
Methods for treating superficial bladder carcinoma
|
|
US20040009212A1
(en)
|
2002-01-30 |
2004-01-15 |
Pharma Power Biotec Co. Ltd. |
Mucoadhesive thermoresponsive medicament-carrier composition
|
|
GB0328060D0
(en)
|
2003-12-04 |
2004-01-07 |
Sod Conseils Rech Applic |
Botulinum toxin treatment
|
|
GB0414825D0
(en)
|
2004-07-02 |
2004-08-04 |
Biostatus Ltd |
Gel formulations and uses thereof
|
|
US20090142259A1
(en)
|
2006-05-12 |
2009-06-04 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
|
|
US9107815B2
(en)
|
2008-02-22 |
2015-08-18 |
Allergan, Inc. |
Sustained release poloxamer containing pharmaceutical compositions
|
|
EP2313122B1
(en)
|
2008-07-17 |
2019-03-06 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
US10471150B2
(en)
|
2010-01-20 |
2019-11-12 |
Urogen Pharma Ltd. |
Material and method for treating internal cavities
|
|
ES2732150T3
(es)
*
|
2010-01-20 |
2019-11-20 |
Urogen Pharma Ltd |
Material y método para tratar cavidades internas
|
|
EP2734187B1
(en)
*
|
2011-07-20 |
2018-09-05 |
UroGen Pharma Ltd. |
Materials and method for treating internal body cavities
|
|
US20140142191A1
(en)
|
2011-07-20 |
2014-05-22 |
Theracoat Ltd. |
Production of thermoreversible hydrogels for therapeutic applications
|
|
PT2865391T
(pt)
*
|
2013-10-22 |
2017-12-22 |
Medac Ges Für Klinische Spezialpräparate Mbh |
Processo para a produção de uma composição farmacêutica liofilizada com um conteúdo de mitomicina c
|
|
US9801854B1
(en)
*
|
2014-01-17 |
2017-10-31 |
Urogen Pharma Ltd. |
Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer
|
|
WO2016004213A2
(en)
|
2014-07-01 |
2016-01-07 |
Vicus Therapeutics, Llc |
Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
|
|
US20170128424A1
(en)
|
2015-11-11 |
2017-05-11 |
Qrono, Inc. |
Sustained release pharmaceutical compositions and methods of use
|
|
JP7265989B2
(ja)
*
|
2016-10-25 |
2023-04-27 |
ウロゲン ファーマ リミテッド |
体腔の免疫調節治療
|
|
WO2018169960A1
(en)
|
2017-03-17 |
2018-09-20 |
The Johns Hopkins University |
Nanoparticle formulations for enhanced drug delivery to the bladder
|
|
EP3498270A1
(en)
*
|
2017-10-30 |
2019-06-19 |
Urogen Pharma Ltd. |
Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer
|
|
US12336979B2
(en)
|
2020-12-11 |
2025-06-24 |
Urogen Pharma Ltd. |
Material and method for treating cancer
|